CD8A and COVID-19: In the case of COVID-19, although SARS-CoV-2 is a novel pathogen, it shares extensive CD4+ and CD8+ T-cell cross reactivity with human endemic coronaviruses (30–32) and would therefore elicit a secondary T-cell response to the cross-reactive epitopes.